Global Antiretroviral Therapy Market 2017-2021 - Product Image

Global Antiretroviral Therapy Market 2017-2021

  • ID: 4427306
  • Report
  • Region: Global
  • 81 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Abbvie
  • Bionor Pharma
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • Gilead
  • Janssen Pharmaceuticals
  • MORE
About Antiretroviral Therapy

The antiretroviral therapy (ART) market is primarily related to the treatment of human immunodeficiency virus (HIV) infection. Antiretroviral drugs are usually taken in combination to prevent the growth of the virus, which slows the growth of HIV infection. The major drivers for the ART market include the rising awareness of retroviral infection, aggressive innovation in diagnostic techniques, the introduction of novel drugs through significant investments made in R&D, and high unmet needs in the retrovirus infection treatment domain.

The analysts forecast the global antiretroviral therapy market to grow at a CAGR of 2.64% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global antiretroviral therapy market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Antiretroviral Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
  • Gilead
  • ViiV Healthcare
  • Janssen Pharmaceuticals
  • F. Hoffmann-La Roche
Other prominent vendors
  • Abbvie
  • Boehringer Ingelheim
  • Bionor Pharma
  • Vertex Pharmaceuticals
  • Mylan
Market drivers
  • Rising awareness of retroviral infection
  • For a full, detailed list, view the full report
Market challenges
  • High cost of antiretroviral drugs
  • For a full, detailed list, view the full report
Market Trends
  • Significant pipeline
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbvie
  • Bionor Pharma
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • Gilead
  • Janssen Pharmaceuticals
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
  • Market outline
PART 05: DISEASE OVERVIEW

PART 06: MARKET LANDSCAPE
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY DRUG CLASS
  • Multiclass combination products
  • NRTIs
  • Integrase inhibitors
  • NNRTIs
  • Others
PART 09: REGIONAL LANDSCAPE
  • Regional comparison
  • ART market in Americas
  • ART market in EMEA
  • ART market in APAC
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Significant pipeline
  • Advanced formulations
  • Funding and treatment initiatives
PART 13: VENDOR LANDSCAPE
  • Vendor landscape
PART 14: KEY VENDOR ANALYSIS
  • Gilead
  • ViiV Healthcare
  • Janssen Pharmaceuticals
  • F. Hoffmann-La Roche
  • Other prominent vendors
PART 15: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Global ART market
Exhibit 02: Global ART market 2016-2021 ($ millions)
Exhibit 03: Five forces analysis
Exhibit 04: Pipeline landscape by development phase
Exhibit 05: Key clinical trials
Exhibit 06: Global ART market by drug class 2016
Exhibit 07: Global ART market by drug class 2021
Exhibit 08: Global ART market by multiclass combination products 2016-2021 ($ millions)
Exhibit 09: Global ART market by NRTIs 2016-2021 ($ millions)
Exhibit 10: Global ART market by integrase inhibitors 2016-2021 ($ millions)
Exhibit 11: Global ART market by NNRTIs 2016-2021 ($ millions)
Exhibit 12: Global ART market by others 2016-2021 ($ millions)
Exhibit 13: Global ART market: Regional landscape
Exhibit 14: Regional comparison
Exhibit 15: ART market in Americas 2016-2021 ($ millions)
Exhibit 16: ART market in Americas – Year over year growth 2017-2021
Exhibit 17: ART market in EMEA 2016-2021 ($ millions)
Exhibit 18: ART market in EMEA – Year over year growth 2017-2021
Exhibit 19: ART market in APAC 2016-2021 ($ millions)
Exhibit 20: ART market in APAC – Year over year growth 2017-2021
Exhibit 21: Gilead: Key highlights
Exhibit 22: Gilead: Strength assessment
Exhibit 23: Gilead: Strategy assessment
Exhibit 24: Gilead: Opportunity assessment
Exhibit 25: ViiV Healthcare: Key highlights
Exhibit 26: ViiV Healthcare: Strength assessment
Exhibit 27: ViiV Healthcare: Strategy assessment
Exhibit 28: ViiV Healthcare: Opportunity assessment
Exhibit 29: Janssen Pharmaceuticals: Key highlights
Exhibit 30: Janssen Pharmaceuticals: Strength assessment
Exhibit 31: Janssen Pharmaceuticals: Strategy assessment
Exhibit 32: Janssen Pharmaceuticals: Opportunity assessment
Exhibit 33: F. Hoffmann-La Roche: Key highlights
Exhibit 34: F. Hoffmann-La Roche: Strength assessment
Exhibit 35: F. Hoffmann-La Roche: Strategy assessment
Exhibit 36: F. Hoffmann-La Roche: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbvie
  • Bionor Pharma
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • Gilead
  • Janssen Pharmaceuticals
  • MORE
New Report Released: – Global Antiretroviral Therapy Market 2017-2021

The author of the report recognizes the following companies as the key players in the global antiretroviral therapy market: Gilead, ViiV Healthcare, Janssen Pharmaceuticals, and F. Hoffmann-La Roche

Other Prominent Vendors in the market are: Abbvie, Boehringer Ingelheim, Bionor Pharma, Vertex Pharmaceuticals, and Mylan

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is Significant pipeline. Several promising antiretroviral agents are in the pipeline, which will boost the market growth in the long run. The approval of new therapeutic agents will broaden the options available for treatment and thus will lead to the increase in demand for therapeutic regimens. There are approximately 37 molecules under different clinical trial stages globally of which 18 molecules are in phase-II, and 13 molecules are in phase-III for various retroviral malignancies. The remaining molecules are in phase-I of their clinical trials.”

According to the report, one of the major drivers for this market is Rising awareness of retroviral infection. The awareness about retroviral infection is on the rise. Initiatives such as the Centers for Disease Control and Prevention's (CDC's) Act Against AIDS, targeted to make the youth aware of the risk of HIV infection because of concurrent use of alcohol and drugs, will drive the growth of the market. The initiatives by various governments also help to create awareness.

Further, the report states that one of the major factors hindering the growth of this market is High cost of antiretroviral drugs. High cost of treatment is one of the major challenges impeding the growth of the global ART market. The majority of patients in low and middle-income countries infected with HIV-1 and diagnosed after confirmatory tests fail to complete the course of treatment due to affordability concerns. According to the NIH, ART's success depends on patient adherence to the therapy course. Patients who had adhered 95% or above have shown a decrease in the viral load; the HIV RNA level was also non-detectable. Hence, the market can only experience growth if demand is high, which can only be possible if individuals are able to afford the cost of treatment. Therefore, it is essential to bring down the cost of drugs and treatment so that drug adherence, as well as adoption rate, improves.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Gilead
  • ViiV Healthcare
  • Janssen Pharmaceuticals
  • F. Hoffmann-La Roche
  • Abbvie
  • Boehringer Ingelheim
  • Bionor Pharma
  • Vertex Pharmaceuticals
  • Mylan
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll